Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Dianthus Therapeutics (DNTH) Non Operating Income (2022 - 2025)

Dianthus Therapeutics has reported Non Operating Income over the past 4 years, most recently at $3.5 million for Q3 2025.

  • Quarterly results put Non Operating Income at $3.5 million for Q3 2025, down 25.45% from a year ago — trailing twelve months through Sep 2025 was $11.0 million (up 19.74% YoY), and the annual figure for FY2024 was $16.9 million, up 28258.33%.
  • Non Operating Income for Q3 2025 was $3.5 million at Dianthus Therapeutics, up from -$107000.0 in the prior quarter.
  • Over the last five years, Non Operating Income for DNTH hit a ceiling of $7.7 million in Q4 2024 and a floor of -$114000.0 in Q1 2024.
  • Median Non Operating Income over the past 4 years was $615000.0 (2023), compared with a mean of $1.9 million.
  • Peak annual rise in Non Operating Income hit 40552.63% in 2024, while the deepest fall reached 119.19% in 2024.
  • Dianthus Therapeutics' Non Operating Income stood at $470000.0 in 2022, then tumbled by 104.04% to -$19000.0 in 2023, then skyrocketed by 40552.63% to $7.7 million in 2024, then crashed by 54.16% to $3.5 million in 2025.
  • The last three reported values for Non Operating Income were $3.5 million (Q3 2025), -$107000.0 (Q2 2025), and -$98000.0 (Q1 2025) per Business Quant data.